CannMed Coffee Talk

Dr. Emily Lindley is Assistant Professor of Orthopedics and Director of the Colorado Cannabis Research Consortium. Her team’s research aims to identify non-opioid alternatives for the treatment of chronic musculoskeletal pain. One such alternative that has gained increased recognition in recent years is medical cannabis, and her lab is currently studying the health effects of cannabis and cannabinoids for chronic musculoskeletal pain. Dr. Rachael Rzasa Lynn is a board certified in pain medicine physician and is an Associate Professor in the Department of Anesthesiology at the University of Colorado, where she is the Associate Program Director for the Pain Medicine Fellowship. Her research includes investigations in opioid pharmacology and the use of cannabis for chronic pain. Emily and Rachael co-authored a poster presented at the most recent ICRS conference titled, Recruitment Challenges in Clinical Studies of Cannabis During our conversation, we discussed: How recruitment for cannabis clinical trials differs from traditional clinical trials Why prior experience with cannabis is considered a negative for patient recruitment How legal concerns and stigma can deter cannabis-naive patients from enrolling Why the particiapnt drop out rate is higher in cannabis trials How rescheduling may affect patient recruitment future trials Thanks to This Episode's Sponsor: The Society of Cannabis Clinicians The Society of Cannabis Clinicians’ Med Cann conference offers a rare opportunity for clinicians to dive deep into the clinical realities and therapeutic potential of medical cannabis and psychedelics. Designed with healthcare providers in mind, their sessions focus on case-based learning, emerging protocols, and real-world challenges—offering practical insights that can be immediately applied in your practice. Learn more at cannabisclinicians.org and use code "CP15" to receive 15% Off Your Registration Additional Resources Recruitment Challenges in Clinical Studies of Cannabis [Poster] Lindley Lab at the University of Colorado

Dr. Jose Lime is a Professor at Southern Illinois University and the principal investigator in the Cannabis Biology and Cultivation Systems lab. He and his team focus on determining how to leverage environmental controls (light intensity, duration, quality, temperature, and CO2), plant nutrition, biostimulants, and hormones to improve plant production. Moreover, the research group is developing techniques to optimize plant yields and quality based on key crop steering traits that increase sustainability and efficiency via plant physiological, biochemical, and agricultural approaches. During our conversation, we discussed several recent studies that Jose and his team have published, including: Using mechanical stimulation and high stress training to increase production of secondary metabolites Applying plant hormones to increase trichome density Assessing how drought stress affects plant yield and potency Standardizing cloning methods for plant propagation Developing standards for measuring trichome density Thanks to This Episode's Sponsor: Advanced Nutrients Founded in 1999, Advanced Nutrients was the first to develop a complete nutrient system that unlocks the true genetic potential of the cannabis plant. Since its inception, the brand has introduced more than 50 innovations to the cultivation community and continues to revolutionize the space through proprietary scientific discoveries.  Learn more at AdvancedNutrients.com Additional Resources DrLeme.com Methyl Jasmonate and Ammonium Bicarbonate: Distinct and Synergistic Impacts on Indoor Cannabis Production Dynamics The Role of Jasmonates in Modulating Growth, Trichome Density, and Cannabinoid Accumulation in Cannabis sativa L. The Effects of Water-Deficit Stress on Cannabis sativa L. Development and Production of Secondary Metabolites: A Review From Bracts to Buds: Developing Reliable Methods for Trichome Density Assessment in Cannabis sativa L. Accumulation of Trigonelline in the Leaves of Cannabis sativa L. in Response to Water-Deficit Stress Implementation of a Standardized Cloning and Propagation Protocol for Optimizing Cannabis sativa L. Cultivation

Dr. Mark Scialdone is a recognized expert in the field of organic chemistry, specializing in natural product chemistry, including plant oil extraction, analysis, and chemical modification. He is an inventor of 37 issued US patents and has authored 17 peer-reviewed publications, during more than two decades of fundamental and product development research. He has given numerous invited lectures at more than 40 different academic institutions and international symposia. At CannMed 25, Mark participated in the Hemp-Derived Cannabinoids panel, which explored the rapid rise of products containing chemically transformed cannabinoids to exploit the 2018 Farm Bill loophole. He also presented a poster that explained the process for chemically converting cannabinoids in more detail. During our conversation we discussed: Why producers and manufacturers would want to convert one cannabinoid into another Common methods for cannabinoid conversion Safety risks associated with chemical cannabinoid conversion The legality of these compounds How these compouns and these products are affecting the legal cannabis market The therapeutic potential of novel, chemically-converted cannabinoids and more Thanks to This Episode's Sponsor: Cannabis & Tech Today Cannabis & Tech Today is the premier publication for the business, science, and innovations shaping the cannabis industry. From exclusive interviews with industry leaders to deep dives on the latest tech, they cover it all. Go to cannatechtoday.com to subscribe to their digital and print editions and gain access to exclusive interviews, brand-new technology, and thought-provoking articles from every corner of the cannabis community. Additional Resources Pre-Register for CannMed 26 for just $100 CannMed Video Archive Connect with Mark on LinkedIn The Dark Side of Cannabidiol (CBD): The Unanticipated Social and Clinical Implications of Synthetic Δ8-THC Hash Church on YouTube CANN Delta-8-THC Panel Discussion GC Separation for Identification of iso-THC Contaminants and Accurate Quantification of Δ8 -THC and Δ9-THC in Cannabis Samples

Another CannMed Summit is in the books. To all of you who joined us in Puerto Rico this year, thank you for making it our best event yet!  This year’s summit brought together clinicians, regulators, researchers, cultivators, patients, and entrepreneurs from more than a dozen countries. The enthusiasm and passion that they brought to the sessions and the networking events created an amazing environment for creating lasting connections. We can’t wait to see how those connections shape the future of the industry.  If you weren’t able to join us this year, don’t worry, you can experience at least part of the CannMed magic when we post video recordings of all the panels and oral presentations on our YouTube page and the CannMed Archive. Those will be posted in the next 30-45 days. Be sure to sign up for email alerts to receive an email when they are live.  We are already looking forward to CannMed 26 and will hopefully have details to share very soon. 2026 is the 10 year anniversary of our very first event, so we are working on some special ways to celebrate.  That’s it for now. No interview today. We are still resetting following the event, but we should be back with a new episode for July 9th.

Dr. Shiksha Gallow currently serves as the Medical Director of the Holistic Integrative Healing Institute and is notably the first and only South African to sit on the Board of Directors of the Society of Cannabis Clinicians. Dr. Gallow’s passion lies in leveraging her medical and scientific expertise to develop Active Pharmaceutical Ingredients (APIs) from cannabis and other plant species to treat various conditions. She has achieved significant success in treating patients with autoimmune diseases and cancer, and she strongly advocates for patient access to safe and effective medicines that improve quality of life. At CannMed 25 she will present “Comprehensive Evaluation of the ‘Impact of Cannabinoids’ on Prostate Cancer: Integrating PSA, PET/CT Scans and Patient-Related Outcomes”  During our conversation we discuss The variety of treatment options for prostate cancer and the role of cannabinoids may play Results from an empirical study that evaluated how cannabinoid treamtment impacts PSA levels PET/CT scans and patient reported outcomes  How patients were selected and grouped for the study  Future research opportunities  and more  Thanks to This Episode's Sponsor: PRICH Biotech PRICH Biotech, Corp. is a vertically integrated company dedicated to the cultivation, manufacture and dispensing of medicinal Cannabis in Puerto Rico.  With over 500,000 square feet of STATE OF THE ART facilities, Prich uses  the highest standards of agricultural and manufacturing practices to Guarantee the highest standard of medicinal cannabis. Their mission is to offer a natural and unique experience through medicinal cannabis that raises the patient's well-being and quality of life. Learn more at prichbiotech.com.  Additional Resources Dr. Gallow on Linkedin Holistic Healing Dr Gallow (Facebook) CannMed Video Archives

Morgan Keefer is the Senior Accreditation Officer at A2LA where she works with and assesses cannabis testing laboratories across the United States.  Since joining A2LA, Morgan has presented about Laboratory Shopping, Proficiency Testing, and Microbial Testing in the cannabis industry at Cannabis Science Conference, A2LA's Annual Conference and PITTCON. At CannMed 25 she will present “Accredited Methods in Cannabis Testing” which will explore many of the challenges facing cannabis testing labs. During our conversation we discuss:  The variation of cannabis testing regulations across the U.S., and how that creates challenges for multi-state labs and manufacturers. The lack of established testing standards, which leads to inconsistent results across the industry  The role organizations like AOAC and USP play in creating standard methods   How inconsistent testing results affect consumer safety  The lack of testing requirements for consumable hemp products  Thank You to This Episode’s Sponsor: McKinney RSA  McKinney is made up of regulatory science veterans who apply lessons learned in the nicotine space to help cannabis manufacturers better understand the toxicological and societal implications of their product.  They do that by Identifying base compounds, extracts, flavors and terpenes, understanding how they interact, and ensuring effectiveness for the intended use. They also provide dosing recommendations and establish guidelines for product consistency.  Learn more at mckinneyrsa.com  Additional Resources NIHC Verify program  A2LA-NIHC Verify Hemp/Cannabis Recognition Program  A2LA Domestic Recognitions  A2LA Public Documents  Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters Review the Podcast CannMed Archive

Dr. Dustin Sulak is a traditional osteopathic physician and expert in integrative medicine. His clinical practice in Maine focuses on treating refractory conditions in adults and children. Dr. Sulak is an internationally-renowned expert in medical cannabis, the author of Handbook of Cannabis for Clinicians: Principles and Practice, and co-founder of Healer, a medical cannabis education resource and products company. He serves on the board of directors of The Society of Cannabis Clinicians and is a passionate educator and leader in the medical cannabis field.  Dustin is also a true CannMed veteran, having participated in every CannMed event dating back to our first conference at Harvard Medical School. He returns to CannMed 25 this year and is contributing to multiple sessions, including: The Cannabinoid Hyperemesis Syndrome Panel CannMed Medical Practicum Bridging the Gap: New Findings on the Utility of CBG-Dominant and THC-Containing Hemp Products Morning Mindfulness Session We discuss: Overview of Dustin's oral presentation on CBG and its clinical use in cannabinoid medicine Current research, anecdotal evidence, and mechanisms of CBG's therapeutic effects Insights from a patient survey studying CBG and THC usage patterns, dosages, and outcomes How the 2018 Farm Bill increased patients' access to THC-containing products Using cannabinoids, especially low-dose THC and CBG, to manage dementia symptoms. Survey data on using ketamine to treat depression and pain Thanks to This Episode’s Sponsor: Healer  Healer is a trusted, physician-developed medical cannabis brand founded to address the challenges of helping patients and health providers get the best results with safe, reliably dosable products and education on how to best use them. Healer’s distinctive product formulations and educational material are based on the work of leading cannabis clinician, Dr. Dustin Sulak, D.O.  Learn More at healer.com Additional Resources  Healer.com  HealerCBD.com Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters – –  Review the Podcast CannMed Archive

Zamir Punja, PhD is a Professor of Plant Biotechnology at Simon Fraser University in Canada. His research interests include the etiology and management of plant diseases on vegetable and horticultural crops, and the applications of plant biotechnology for disease management. Since 2018, his work has shifted to researching cannabis, where his group has described a range of previously unreported pathogens affecting the crop and has evaluated various methods for disease management. At CannMed 25, Zamir will present his team’s latest work investigating the microbiome of cannabis and hemp plants. Using Next-Generation Sequencing and microscopy, his team identified diverse fungi, yeasts, and bacteria across plant tissues. Their study reveals that cannabis plants host abundant microbial endophytes, which can impact plant health and product quality. Findings also highlight the influence of growing substrates and biocontrol agents on the cannabis microbiome. During our conversation, we discuss: What is the microbiome and how do microbial endophytes affect plant health Identification of common microbes found in cannabis samples, including Penicillium and Fusarium Whether meristem tissue culture is a viable microbial sterilization method The influence of sterilized vs. non-sterilized growing media How growers can use microbiome analysis for early interventions Insights into beneficial fungi like Trichoderma and Mycorrhizae Future research questions on microbial balance and seed microbiome engineering And More Thanks to This Episode’s Sponsor: GrowDefender GrowDefender provides long-lasting antimicrobial protection for indoor cultivation and processing spaces. Using patented Goldshield® technology, their EPA-registered, water-based products protect surfaces from mold, mildew, bacteria, and fungi for up to 90 days. Safe, non-toxic, and easy to apply, GrowDefender helps growers reduce contamination, protect crops, and maintain cleaner, healthier environments. Learn more at growdefender.com Additional Resources Endophytes in Cannabis sativa: Identifying and Characterizing Microbes with Beneficial and Detrimental Effects on Plant Health - https://pmc.ncbi.nlm.nih.gov/articles/PMC12030312/ Exploring the fascinating development of cannabinoid-producing trichomes - https://youtu.be/Avhr8XjsBTU?si=nbYpjuoMMnKVqF6X Register for CannMed 25 - https://cvent.me/emBPno Meet the CannMed 25 Speakers and Poster Presenters - https://cannmedevents.com/speakers/ - Review the Podcast - https://podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804 CannMed Archive - https://cannmedevents.com/cannmed-video-archives/

Dr. Dedi Meiri is an Associate Professor at the Technion Institute where he heads the Laboratory of Cancer Biology and Cannabinoid Research. The lab investigates the vast therapeutic potential of secondary metabolites from cannabis and other herbs, algae, and psychedelic mushrooms; and reveals how these naturally occurring metabolites affect various types of cancer, inflammatory diseases, and disorders of the nervous system Dr. Meiri is also highly involved in governmental regulations and is a residing member in several Israeli Ministry of Health committees that seek to advance the fundamental understanding of optimal cannabis and other psychedelic plant usage and curtailing adverse effects. At CannMed 25, Dedi will present "Cannabis as a Therapy Across Diverse Cancer Types: Milestones and Insights from a Decade of Research", which will discuss his lab’s work investigating whether Cannabis can serve as a primary pharmaceutical treatment for cancer. We discuss: The wide range of clinical applications for cannabis medicine, including cancer, epilepsy, sleep disorders, Alzheimer’s, and women’s health issues like endometriosis. How cannabis’ entourage effect challenges the traditional one-drug-one-target model. How many powerful cannabinoids are overlooked by standard lab testing methods—even though they exist in significant quantities and show therapeutic potential. Israel’s Medical Cannabis Model, which treats cannabis like a pharmaceutical, with prescriptions, clinical oversight, and growing physician acceptance. The goal is to provide evidence-based, accurate treatments that tailor cannabis therapies to specific health conditions and individual needs. Thanks to This Episode’s Sponsor: Trusted Canna Nurse Trusted Canna Nurse was founded by Megan Mbengue and Ariane Williams, two nurses who are dedicated to bridging the gap between traditional medicine and the world of cannabis and psychedelics. They specialize in creating evidence-based treatment plans for all ages that address chronic illnesses, treatment-resistant conditions, mental health, autism, and more. Learn more at trustedcannanurse.com Additional Resources Dedi Meiri Publications on Google Scholar Dedi Meiri on Linkedin Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters Review the Podcast CannMed Archive

Michael Petersen has over 38 years of experience as a researcher and mentor in both the private and public plant biotech space. He has over 50 issued patents and his work in plant transformation and gene expression is a passion. Mike has worked on many genetic engineering/editing contracts with entities across the globe, and he now focuses on innovative hemp research. At CannMed 25, Mike will share his team’s latest efforts to transform cannabis and hemp plants using gene editing and genetic engineering in a presentation titled, “Creation of Novel Traits Through Genetic Engineering and Editing of Cannabinoid, Terpene, and Flavonoid Pathways in Cannabis sativa” During the conversation, we discussed: The difference between gene editing and genetic engineering How gene editing and genetic engineering methods have changed over the years Potential applications of gene editing and genetic engineering in cannabis and hemp Benefits and challenges versus traditional breeding The Wisconsin Crop Innovation Center’s gene editing service, which is available to researchers and cultivators Thanks to This Episode's Sponsor: Kannapedia.net Kanapedia.net is the world’s most comprehensive cannabis genomic library, featuring more than 2,200 genomic reports on cannabis and hemp varieties from around the globe. Kannapedia.net reports are easily searchable and contain Visualizations and Variant Tables that highlight high-impact variants in genes of interest. For example, you can see a report for the Badger G variety that Mike Petersen’s team edited to break the CBDA synthase gene. In fact, you can see the drop out in the CBDA coverage chart on that report. . Visit Kannapedia.net to learn more. Additional Resources Wisconsin Crop Innovation Center Email Mike Michael Petersen on Linkedin Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters Review the Podcast CannMed Archive

Israel Gasperin is a visionary entrepreneur, engineering scientist and the founder of Zentrela, a company dedicated to transforming cannabis research through advanced neurotechnology and AI. Under Israel’s leadership, Zentrela developed the Psychoactive Effect Level (PEL) metric, an innovative EEG-based measure capable of objectively assessing cannabis products' psychoactive potency. By combining wearable EEG technology with AI-driven EEG analysis, the PEL metric provides cannabis producers, researchers, and regulators with a non-invasive and cost-effective way to quantify product effects and maintain quality control.  At CannMed 25, Israel will share results from over 10,000 EEG scans of consumers using a wide range of cannabis products in his oral presentation titled “Cannabis Effect Research Driven by EEG Technology and Machine Learning”. During our conversation, we discuss:  How Zentrela’s wearable EEG technology got its start measuring drowsiness in truck drivers   The unreliability of consumer feedback with regards to cannabis product effects  How the PEL metric was created to measure the unique psychoactive effects of cannabis How producers can use PEL to objectively measure the quality and effectiveness of cannabis products beyond cannabinoid percentages  Research findings that show THC% and PEL% are not directly correlated  and more  Thanks to This Episode’s Sponsor: The DENT Institute With more than 300,000 patient visits per year, the DENT Neurologic Institute ranks among the largest neuroscience centers in North America. Its 24 subspecialty clinics often treat the most challenging neurologic conditions including but not limited to Migraine, Chronic pain, ALS, MS, Parkinson’s, Dementia, and Neuro-Oncology. With their mission of advancing neuroscience, the Dent Institute established a cannabis clinic in 2016 to aid in the treatment of these chronic conditions seen throughout the institute. Learn more at dentinstitute.com Additional Resources Zentrela Website Israel Gasperin on LinkedIn Use of a Novel EEG-Based Objective Test, the Cognalyzer®, in Quantifying the Strength and Determining the Action Time of Cannabis Psychoactive Effects and Factors that May Influence Them Within an Observational Study Framework Sensitivity, Specificity and Accuracy of a Novel EEG-Based Objective Test, the Cognalyzer®, in Detecting Cannabis Psychoactive Effects Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters Review the Podcast CannMed Archive

Shawna Vreeke, PhD is Head of Research at True Terpenes, where she is instrumental in developing and maintaining the rigorous safety and quality protocols the brand is known for. Shawna is an active advocate for science-based safety parameters to protect consumer health and has worked with policymakers to implement sensible regulations to protect public health and maintain access to regulated cannabis products. She has multiple peer-reviewed papers on vape safety, and most recently, her work has been adopted into two ASTM global standards. At CannMed 25 Shawna will present Toxicological Risk in Cannabis Vapes: Exogenous Additives and Their Implications for Consumer Safety. It will highlight specific higher-risk ingredients and identify how prevalent they are in vaporization products currently in the cannabis market.  During our conversation we discussed:  The main components of cannabis vape products  How and why exogenous ingredients are added to vape products How toxicological risks are evaluated based on hazard and exposure level  Why one can’t assume that safe food ingredients are also safe for inhalation  Why risk-assessment based regulations are a better approach to outright bans on flavors and more  Additional Resources True Terpenes website Connect with Shawna Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters Review the Podcast CannMed Archive

Dr. Staci Gruber is the Director of the Cognitive and Clinical Neuroimaging Core at McLean Hospital’s Brain Imaging Center and an Associate Professor of Psychiatry at Harvard Medical School. Dr. Gruber launched Marijuana Investigations for Neuroscientific Discovery (MIND) in 2014, the first ever program of its kind designed to clarify the long-term impact of medical cannabis use. MIND supports numerous projects that aim to address the impact of medical cannabis on a number of important variables including cognition, brain structure and function, clinical state, quality of life, pain, sleep, and other health-related measures. As director of MIND, Dr. Gruber has generated major contributions to the field as the first to assess medical cannabis patients longitudinally, first to acquire neuroimaging data in medical cannabis patients, and as Principal Investigator of the first clinical trial of a full-spectrum, high-cannabidiol (CBD) product, which she specifically formulated to treat anxiety. Additional, novel clinical trials have been approved and are pending or currently underway. At CannMed 25 Staci will share findings from those clinical trials as an oral presenter. https://cannmedevents.com/staci-gruber-phd/ Topics Discussed: Key findings from the MIND Program’s longitudinal studies on medical cannabis use (improved cognitive performance and reductions in pain, anxiety, and sleep disturbances) Ongoing clinical trials the MIND Program is conducting on anxiety, bipolar disorder, and Alzheimer’s The Women’s Health Initiative at MIND (WHIM) investigating cannabis for gynecologic pain, menopause, and endometriosis Concerns about mislabeled cannabis products and unregulated hemp-derived products and more! Thanks to This Episode's Sponsor: Healer Healer is a trusted, physician-developed medicinal cannabis brand founded to address the challenges of helping people and health providers get the best results with safe, reliably dosable products and education on how to best use them. Healer Hemp products are available nationwide and include a step-by-step usage guide and response tracker. Healer’s distinctive product formulations and education are based on the latest research and work of leading cannabis clinician, Dr. Dustin Sulak, D.O. Visit Healer.com or HealerCbd.com Additional Resources https://www.drstacigruber.com Social Media: @DrStaciGruber on X and Instagram Register for CannMed 25 Meet the CannMed 25 Speakers Review the Podcast CannMed Archive

Dr. Punya Nachappa is an Associate professor at Colorado State University in the Department of Agricultural Biology. Her research program focuses on understanding the interactions between plants and insect vectors to manage plant pests and diseases in hemp. At CannMed 25, Punya will present "Biology and Management of Hop Latent Viroid", which will describe the impact of HLVd on hemp yield and cannabinoids, explain how thrips and aphids transmit the viroid, and evaluate the efficacy of using chemical elicitors to control HLVd infections. During our conversation, we discussed: How Hop Latent Viroid has been reported in every hemp-growing state in the US and Canada How HLVd spreads through infected clones, mechanical contact, seeds, and insect vectors like aphids and thrips. Possible reasons why hemp varieties appear more resistant than cannabis varieties (i.e., genetic diversity and environmental factors) The tradeoffs associated with using chemical elicitors on infected plants: increased yield, but reduced cannabinoids. Strategies for preventing HLVD spread, including strict sanitation, insect monitoring, frequent testing, and breeding for genetic resistance. Thanks to This Episode's Sponsor: Advanced Nutrients. Founded in 1999, Advanced Nutrients was the first to develop a complete nutrient system that unlocks the true genetic potential of the cannabis plant. Since its inception, the brand has introduced more than 50 innovations to the cultivation community and continues to revolutionize the space through proprietary scientific discoveries.  Learn more at AdvancedNutrients.com Additional Resources - Nachappa Lab Website (https://www.nachappalab.com/) - Register for CannMed 25 (https://cvent.me/emBPno) - Meet the CannMed 25 Speakers (https://cannmedevents.com/speakers/) - Review the Podcast (https://podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804) - CannMed Archive (https://cannmedevents.com/cannmed-video-archives/)

Dr. Michelle Peace is an internationally recognized forensic toxicologist and a Full Professor in the Department of Forensic Science at Virginia Commonwealth University. The National Institute of Justice has funded her team to study the proliferation of semi-synthetic THC analogs in the unregulated market and define their relevant biomarkers. Her work impacts public health and public safety policies and initiatives. At CannMed 25 Michelle will present “Why Some People “Green Out”? The Analysis of Unregulated “Hemp-derived” Cannabis Products”. Her team used a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to analyze unregulated hemp products. All the products they analyzed were mislabeled in some way, either misrepresenting the cannabinoids contained therein or their concentrations.  During our conversation we discuss What has caused the rise of semi-synthetic cannabinoids in the market?  How Michelle got involved testing unregulated hemp and cannabis products  Some of the adverse events that have occured from consuming semi-synthetic cannabinoids  How the LS-MS/MS method allows Michelle’s team to see compounds other labs can’t   How consumers can protect themselves from mislabeled products Whether federal legalization of cannabis would eliminate the semi-synthetic market  Thanks to This Episode's Sponsor: PRICH Biotech PRICH Biotech, Corp. is a vertically integrated company dedicated to the cultivation, manufacture and dispensing of medicinal Cannabis in Puerto Rico.  With over 500,000 square feet of state-of-the-art facilities, Prich uses the highest standards of agricultural and manufacturing practices to guarantee the highest standard of medicinal cannabis. Their mission is to offer a natural and unique experience through medicinal cannabis that raises the patient's well-being and quality of life. Learn more at prichbiotech.com.  Additional Resources Register for CannMed 25 Meet the CannMed 25 Speakers Review the Podcast CannMed Archive